130 related articles for article (PubMed ID: 37681509)
21. Reprogramming and Differentiation of Cutaneous Squamous Cell Carcinoma Cells in Recessive Dystrophic Epidermolysis Bullosa.
Rami A; Łaczmański Ł; Jacków-Nowicka J; Jacków J
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383666
[TBL] [Abstract][Full Text] [Related]
22. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006.
Fine JD; Johnson LB; Weiner M; Li KP; Suchindran C
J Am Acad Dermatol; 2009 Feb; 60(2):203-11. PubMed ID: 19026465
[TBL] [Abstract][Full Text] [Related]
23. Squamous cell carcinoma complicating epidermolysis bullosa in a 6-year-old girl.
Shivaswamy KN; Sumathy TK; Shyamprasad AL; Ranganathan C
Int J Dermatol; 2009 Jul; 48(7):731-3. PubMed ID: 19570079
[TBL] [Abstract][Full Text] [Related]
24. MMP13 can be a useful differentiating marker between squamous cell carcinoma and benign hyperkeratotic lesions in recessive dystrophic epidermolysis bullosa.
Hata H; Abe R; Suto A; Homma E; Fujita Y; Aoyagi S; Shimizu H
Br J Dermatol; 2015 Mar; 172(3):769-73. PubMed ID: 25066310
[TBL] [Abstract][Full Text] [Related]
25. Significance of sentinel node biopsy in the management of squamous cell carcinoma arising from recessive dystrophic epidermolysis bullosa.
Rokunohe A; Nakano H; Aizu T; Kaneko T; Nakajima K; Ikenaga S; Matsuzaki Y; Murai T; Tamai K; Sawamura D
J Dermatol; 2008 Jun; 35(6):336-40. PubMed ID: 18578710
[TBL] [Abstract][Full Text] [Related]
26. Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma.
Arbiser JL; Fan CY; Su X; Van Emburgh BO; Cerimele F; Miller MS; Harvell J; Marinkovich MP
J Invest Dermatol; 2004 Oct; 123(4):788-90. PubMed ID: 15373786
[TBL] [Abstract][Full Text] [Related]
27. Electrochemotherapy, a local treatment for squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa.
Bartolo J; Farricha V; Carvalhal S; Moura C; Abecasis N
Dermatol Ther; 2020 Nov; 33(6):e14093. PubMed ID: 32720460
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: a 28-year Retrospective Study.
Robertson SJ; Orrin E; Lakhan MK; O'Sullivan G; Felton J; Robson A; Greenblatt DT; Bernardis C; McGrath JA; Martinez AE; Mellerio JE
Acta Derm Venereol; 2021 Aug; 101(8):adv00523. PubMed ID: 34230977
[TBL] [Abstract][Full Text] [Related]
29. Squamous cell carcinoma secondary to recessive dystrophic epidermolysis bullosa. A report of 4 patients with 17 primary cutaneous malignancies.
Newman C; Wagner RF; Tyring SK; Spigel GT
J Dermatol Surg Oncol; 1992 Apr; 18(4):301-5. PubMed ID: 1560154
[TBL] [Abstract][Full Text] [Related]
30. The Role of miR-200b-3p in Modulating TGF-β1-induced Injury in Human Bronchial Epithelial Cells.
Ladak SS; Roebuck E; Powell J; Fisher AJ; Ward C; Ali S
Transplantation; 2019 Nov; 103(11):2275-2286. PubMed ID: 31283671
[TBL] [Abstract][Full Text] [Related]
31. Basic fibroblast growth factor: a missing link between collagen VII, increased collagenase, and squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.
Arbiser JL; Fine JD; Murrell D; Paller A; Connors S; Keough K; Marsh E; Folkman J
Mol Med; 1998 Mar; 4(3):191-5. PubMed ID: 9562977
[TBL] [Abstract][Full Text] [Related]
32. Spliceosome-mediated RNA trans-splicing facilitates targeted delivery of suicide genes to cancer cells.
Gruber C; Gratz IK; Murauer EM; Mayr E; Koller U; Bruckner-Tuderman L; Meneguzzi G; Hintner H; Bauer JW
Mol Cancer Ther; 2011 Feb; 10(2):233-41. PubMed ID: 21209069
[TBL] [Abstract][Full Text] [Related]
33. Squamous cell carcinoma secondary to recessive dystrophic epidermolysis bullosa: report of eight tumours in four patients.
Bosch RJ; Gallardo MA; Ruiz del Portal G; Snchez P; Arce MF; Herrera E
J Eur Acad Dermatol Venereol; 1999 Nov; 13(3):198-204. PubMed ID: 10642056
[TBL] [Abstract][Full Text] [Related]
34. The clinical spectrum of dystrophic epidermolysis bullosa.
Horn HM; Tidman MJ
Br J Dermatol; 2002 Feb; 146(2):267-74. PubMed ID: 11903238
[TBL] [Abstract][Full Text] [Related]
35. Stromal microenvironment in type VII collagen-deficient skin: The ground for squamous cell carcinoma development.
Guerra L; Odorisio T; Zambruno G; Castiglia D
Matrix Biol; 2017 Nov; 63():1-10. PubMed ID: 28126522
[TBL] [Abstract][Full Text] [Related]
36. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1.
Sun L; Yao Y; Liu B; Lin Z; Lin L; Yang M; Zhang W; Chen W; Pan C; Liu Q; Song E; Li J
Oncogene; 2012 Jan; 31(4):432-45. PubMed ID: 21725369
[TBL] [Abstract][Full Text] [Related]
37. Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis Bullosa.
Trefzer L; Hess ME; Scholten L; Technau-Hafsi K; Meiss F; Boerries M; Has C; Rafei-Shamsabadi D
Acta Derm Venereol; 2023 Jun; 103():adv4870. PubMed ID: 37338146
[TBL] [Abstract][Full Text] [Related]
38. Heterogeneous addiction to transforming growth factor-beta signalling in recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma.
Dayal JHS; Mason SM; Salas-Alanis JC; McGrath JA; Taylor RG; Mellerio JE; Blyth K; South AP; Inman GJ
Br J Dermatol; 2021 Apr; 184(4):697-708. PubMed ID: 32726455
[TBL] [Abstract][Full Text] [Related]
39. Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma.
Kivisaari AK; Kallajoki M; Ala-aho R; McGrath JA; Bauer JW; Königová R; Medvecz M; Beckert W; Grénman R; Kähäri VM
Br J Dermatol; 2010 Oct; 163(4):726-35. PubMed ID: 20586780
[TBL] [Abstract][Full Text] [Related]
40. Transcriptome-Guided Drug Repurposing for Aggressive SCCs.
Zauner R; Wimmer M; Dorfer S; Ablinger M; Koller U; Piñón Hofbauer J; Guttmann-Gruber C; Bauer JW; Wally V
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
